Diseases of the Chest
Clinical Evaluation of Toryn, A New Synthetic Cough Depressant*

https://doi.org/10.1378/chest.25.5.532Get rights and content

  • 1)

    Twenty-three patients with severe, chronic cough and underlying advanced organic broncho-pulmonary disease were given the new antitussive drug toryn in dosage of 10 mg. thrice daily for one week. This drug was compared to placebo, codeine sulfate, 16.2 mg., and dihydrocodeinone bitartrate, 5 mg., administered in identical manner, using the “double blind test”.

  • 2)

    Toryn was accompanied by partial to considerable relief from distressing cough in 57 per cent of patients, of which 54 per cent preferred toryn to codeine and dihydrocodeinone in the above dosage.

  • 3)

    Drowsiness and dizziness appear to be side effects of toryn, especially upon administration of larger doses. Nausea was encountered in an occasional patient and may have been related to toryn, at least with the larger doses.

  • 4)

    Toryn decreased the amount of sputum in 61 per cent of patients. There was no clinical evidence of retention of secretions.

  • 5)

    When the percentage of days on which cough was decreased is compared, toryn takes its place between placebo on the one hand and codeine or dihydrocodeinone on the other.

Section snippets

Material and Methods

Twenty-six patients were selected on the basis of severe, irritating, chronic cough as the presenting complaint. Those were excluded who had predominantly productive cough and especially if there was evidence of retention of secretions. Only those who gave promise of cooperation and some ability of self-observation were accepted. With few exceptions they had pulmonary disease of long standing with advanced organic pulmonary changes demonstrated by roentgenograms. All were partially or totally

Results

Twenty of the 26 patients selected for study completed the full course consisting of four consecutive weeks of one week on each drug. Two of these 20 (Nos. 9 and 15) lost one or more of the weekly report cards. Of the remaining six, five (Nos. 2, 3, 4, 8, 10) took two or more drugs for a full week but defaulted on the others. One with far advanced tuberculosis (No. 25) who had previously found some relief with 10 mg. of didhydrocodeinone bitartrate, refused each medication in turn when he

Discussion

The present investigation was carried out to determine if the antitussive properties of toryn could be confirmed in a controlled study of patients with advanced pulmonary disease and severe cough.

The results indicate that some patients with severe chronic irritant cough found partial to considerable relief with toryn. With rather small doses, toryn takes a place in effectiveness between placebo on the one hand and codeine and dihydrocodeinone on the other. The patients selected represent the

Summary

  • 1)

    Twenty-three patients with severe, chronic cough and underlying advanced organic broncho-pulmonary disease were given the new antitussive drug toryn in dosage of 10 mg. thrice daily for one week. This drug was compared to placebo, codeine sulfate, 16.2 mg., and dihydrocodeinone bitartrate, 5 mg., administered in identical manner, using the “double blind test”.

  • 2)

    Toryn was accompanied by partial to considerable relief from distressing cough in 57 per cent of patients, of which 54 per cent preferred

Resumen

  • 1)

    Se dió la nueva droga Toryn a la dosis de diez mg. tres veces al día, a veintitrés enfermos con tos severa, crónica, con avanzada enfermedad broncopulmonar. La droga fué comparada con substitutoneutro, con sulfato de codeína a la dosis de 16.2 mg. y con la dihidrocodeinona en bitar-trato a la dosis de 5 mg. Todas estas substancias fueron administradas de idéntica manera, usando la “doble prueba ciega”.

  • 2)

    El uso de Toryn, fué seguido con una mejoría parcial o considerable de tos agobiante en

Resume

  • 1)

    23 malades atteints de toux sévère chronique due à une affection organique bronchopulmonaire avancée, furent traités avec la nouvelle drogue, la “toryn” à la dose de 10 mmgr. trois fois par jour pendant une semaine. Ce produit est comparé avec des produits factices et avec le sulfate de codéine, 16.2 mmgr. et le bitartrate dihydrocodéinone, 5 mmgr., administrés de manière identique.

  • 2)

    La “toryn” produisit un soulagement partiel, mais considérable de la toux incoercible chez 57% des malades; 54%

References (5)

  • LiechtiJ.

    “Taoryl, ein neues hustenstillendes Mittel,”

    Schweiz. med. Wchnschr

    (1950)
  • SvobodaH.

    “Therapeutische Notiz uber Taoryl, ein neues Hustenmittel mit broncholytischer Wirkung,”

    Praxis

    (1950)
There are more references available in the full text version of this article.

Cited by (4)

  • Caramiphen edisylate: An optimal antidote against organophosphate poisoning

    2014, Toxicology
    Citation Excerpt :

    Caramiphen was less effective than an equal dose of codeine. Sporadic reports of the beneficial effects of caramiphen in the relief of cough were published but only few of them were double-blind controlled trials (Liechti, 1950; Svoboda, 1950; Birkner, 1952; Hudson et al., 1952; Sporn, 1952; Segal and Dulfano, 1953; Segal et al., 1953; Snyder, 1953; Abelmann et al., 1954; Cass and Frederik, 1956; Banyai, 1960; Dreyer, 1961; Glick, 1963). For example, in a cross-over study, Abelmann et al. (1954) showed caramiphen to be an effective antitussive in patients suffering from severe chronic irritating cough.

  • Antitussive drugs-past, present, and future

    2014, Pharmacological Reviews

This study was supported (in part) by research grants from the Committee on Medical Research, National Tuberculosis Association; and the National Institutes of Health, Public Health Service.

*

From the Thorndike Memorial Laboratory, Second and Fourth Medical Services (Harvard), Boston City Hospital and the Department of Medicine, Harvard Medical School; and from the Sanatorium Division of the Boston City Hospital, Mattapan, and the Department of Surgery, Boston University School of Medicine.

View full text